Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality7/10

Pharvaris Advances Deucrictibant toward Regulatory Milestones with Cash Runway Into 2028

Aug 12, 2026, 6:54 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Regulatory milestones (FDA NDA, EMA validation), imminent CHAPTER-3 topline data, and a funded runway support potential rerating. Dilution risk from the €132m offering is a counterpoint, but near-term catalysts and launch-readiness count in PHVS's favor.

AI summary

What happened, with direct paths to the underlying reporting

Pharvaris reports Q2 2026 results while advancing deucrictibant through pivotal trials and regulatory reviews. Key near-term catalysts include CHAPTER-3 topline data in 3Q2026, FDA NDA timing for IR in 2027, and EMA MAA validation, supported by a €132m offering that extends cash runway to 2028. These developments could position Pharvaris for U.S. launch readiness and potential lifecycle opportunities.

CHAPTER-3 topline data due 3Q2026 for deucrictibant XR prophylaxis.
FDA NDA for IR deucrictibant under review; PDUFA date 4/23/2027.
EMA validated MAA for IR; CREAATE enrollment ongoing.
Q2 2026 cash €318m; €132m offering extends runway to 2028.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Pharvaris Advances Deucrictibant toward Regulatory Milestones with Cash Runway Into 2028

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows